Try our beta test site

The Impact of Nebivolol Versus Metoprolol on Quality of Life

This study has been terminated.
(due to slow enrollment)
Forest Laboratories
Lahey Clinic
Information provided by (Responsible Party):
Steven Gabardi, Brigham and Women's Hospital Identifier:
First received: September 26, 2011
Last updated: July 15, 2013
Last verified: July 2013

September 26, 2011
July 15, 2013
February 2012
July 2013   (Final data collection date for primary outcome measure)
Quality of Life [ Time Frame: 12 weeks ]
Primary outcome measure will be the change from the Screening/Enrollment Visit to the End of the Study/Early Termination visit in scores of four quality of life questionnaires.
Same as current
Complete list of historical versions of study NCT01441570 on Archive Site
  • Blood Pressure [ Time Frame: 12 weeks ]
    Evaluate the number of subjects in the nebivolol group that are at goal blood pressure (120/80 mmHg) as compared to those in the metoprolol succinate group.
  • Cost-effectiveness [ Time Frame: 12 weeks ]
    Evaluate the cost-effectiveness of nebivolol as compared to metoprolol succinate.
  • Urine Protein and calculated GFR [ Time Frame: 12 weeks ]
    Evaluate change in urinary protein excretion and calculated glomerular filtration rate in subjects in the nebivolol group as compared with those in the metoprolol succinate group.
Same as current
Not Provided
Not Provided
The Impact of Nebivolol Versus Metoprolol on Quality of Life
The Impact of Nebivolol Versus Metoprolol on Quality of Life Measures and Cost-effectiveness in Stable Renal Transplant Recipients

In an open label analysis, nebivolol has been shown to have a positive impact on quality of life in the general hypertensive population. That is, patients treated with nebivolol reported less side effects compared to those treated with metoprolol. Also, more nebivolol treated patients reached normalization of blood pressure. Although there is no data, it is believed that the impact would be similar in renal transplant recipients.

The primary goal of this study is to determine if nebivolol will improve the quality of life measurements of kidney transplant recipients as compared to those treated with metoprolol succinate. This will be measured by comparing the scores of four quality of life questionnaires taken before and after 12 weeks of treatment with study drug. Other aims of this study are to determine if the use of nebivolol is cost-effective in the renal transplant recipient; determine if there is a change in urine protein excretion and renal function with the use of nebivolol; and determine the number of patients that maintain or achieve a target blood pressure of ≤ 120/80 mmHg.

Not Provided
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
  • Transplant; Failure, Kidney
  • Hypertension
  • Drug: Nebivolol
    Subject will take nebivolol daily for 12 weeks.
    Other Name: Bystolic
  • Drug: Metoprolol succinate
    Subject will take metoprolol succinate daily for 12 weeks.
    Other Name: Toprol XL
  • Active Comparator: Nebivolol
    Intervention: Drug: Nebivolol
  • Active Comparator: Metoprolol Succinate
    Intervention: Drug: Metoprolol succinate
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
July 2013
July 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult renal transplant recipients, men and women between 18 and 75 years of age, inclusive.
  • Patients must be > 3 months post-transplant.
  • Patients must have stable renal function (stable renal function will be defined as those patients without infection or hospitalization [for any reason] over the past 30 days, and patients with < 20% change in their serum creatinine over the past 30 days.
  • Patients receiving corticosteroids must be receiving a daily dose of < 7.5 mg of prednisone (or therapeutic equivalents based on glucocorticoid equivalency scale).
  • All eligible patients must be receiving antihypertensive medication management which must include metoprolol tartrate or metoprolol succinate.
  • Patients may be on more than one medication to control their hypertension. Use of any other FDA-approved antihypertensive agent is permitted.
  • All eligible patients will either be at goal blood pressure (<120/80 mmHg) or have Pre-hypertension (<140/90 mmHg) or Stage I hypertension (<160/100 mmHg) at the time of study inclusion.
  • Patients who are able to comprehend and satisfactorily comply with protocol requirements.
  • Patients who signed the written informed consent given prior to entering any study procedure.

Exclusion Criteria:

  • Patients with Stage II/uncontrolled hypertension (>159/99 mmHg).
  • Patients with an easily identifiable etiology for fatigue (i.e. anemia, iron-deficiency, poor sleep patterns, etc.).
  • Patients who have a medical condition that, in the Investigator's opinion, would expose them to an increased risk of a significant adverse event or interfere with assessments of safety and efficacy during the course of the trial (i.e. arrhythmia).
  • Patients with any current malignancy, or any clinically significant hematological, endocrine, cardiovascular, hepatic, gastrointestinal or neurological disease (including any form of epilepsy). If there is a history of such disease but the condition has been stable for at least the past year and is judged by the investigator not to interfere with the patient's participation in the study, the patient may be included.
  • Patients who are judged by the investigator to be unable or unlikely to follow the study protocol and complete all scheduled visits.
  • Patients with any contraindications to beta blocker therapy as listed in the package labeling for both metoprolol succinate and nebivolol.
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Steven Gabardi, Brigham and Women's Hospital
Brigham and Women's Hospital
  • Forest Laboratories
  • Lahey Clinic
Principal Investigator: Steven Gabardi, PharmD, FCCP, BCPS Transplant Surgery
Brigham and Women's Hospital
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP